Navigation Links
Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
Date:1/25/2012

SAN DIEGO, Jan. 25, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the completion of an underwritten public offering of 14,950,000 shares of its common stock, including 1,950,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters. All of the shares were offered by Sequenom at a price to the public of $4.15 per share. The gross proceeds to Sequenom from this offering were approximately $62.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Sequenom.  Sequenom anticipates using the net proceeds from the offering for general corporate purposes, including research and development expenses, capital expenditures, working capital and general administrative expenses.

Jefferies & Company, Inc. acted as sole book-running manager for the offering, and Oppenheimer & Co. Inc. and William Blair & Company, L.L.C. acted as co-managers for the offering.

The securities described above were offered by Sequenom pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which the SEC declared effective on December 21, 2011.  A final prospectus supplement related to the offering was filed with the SEC and is available on the SEC's website located at http://www.sec.gov.  Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th floor, New York, NY 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Sequenom's expectations with respect to the application of the net proceeds from the offering, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties detailed in Sequenom's current report on Form 8-K filed with the SEC on January 19, 2012 and other filings. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
2. Sequenom Named to NASDAQ Global Select Market
3. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
4. Sequenom to Host Analyst Day on Monday, November 14, 2011
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
7. Sequenom Center for Molecular Medicine Announces Launch of MaterniT21™ Noninvasive Prenatal Test for Down Syndrome
8. Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System
9. Sequenom, Inc. Announces Date of Second Quarter 2011 Financial Results and Conference Call
10. Sequenom Enters Into New $30.0 Million Credit Facility
11. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Calif. , Feb. 17, 2017  BioGenex, ... to announce development of a novel system for ... collaboration with the University of Rochester (NY, USA) ... ). The new system is able to accurately ... biomarker, HER2 (Human epidermal growth factor receptor-2) in ...
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will ... event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan ... organization. They provide an opportunity to interact with peers, make new connections and talk ...
(Date:2/16/2017)... , Feb. 16, 2017 ... "Synthetic Biology: Global Markets" report to their ... ... products (synthetic genes, biobrick parts, delivery plasmids, chassis organisms, ... synthesis and assembly, genome editing, bioinformatics and specialty media) ...
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
Breaking Biology Technology:
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... offering. ... global voice recognition biometrics market to grow at a CAGR of ... the present scenario and the growth prospects of the global voice ... report considers the revenue generated from the sales of voice recognition ...
(Date:1/18/2017)... Jan. 18, 2017 MedNet Solutions ... supports the entire spectrum of clinical research, is ... record-breaking year for the organization in terms of ... MedNet,s eClinical products and services. The company,s exceptional ... success of iMedNet ™ ...
Breaking Biology News(10 mins):